Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP1 | P53582 | 2/20 | 0.42 |
| ▸ | MMP12 | P39900 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10926837 | 0.79 | ESR2 (0.42) | BRD4CREBBPMAOBKDM4EALDH1A1 | |
| SCHEMBL9200636 | 0.79 | TDP2 (0.41) | ACHEPARP10PARP1MAOBKMT2A | |
| SCHEMBL8799090 | 0.78 | METAP1 (0.47) | METAP1ACHEMAOBKDM4EALDH1A1 | |
| SCHEMBL7349547 | 0.77 | MAPT (0.49) | KDM4E | |
| SCHEMBL29408741 | 0.75 | MAOA (0.48) | MAOB | |
| SCHEMBL6937 | 0.75 | MAOA (0.48) | MAOB | |
| SCHEMBL7348992 | 0.73 | ATM (0.50) | EPHX2ALDH1A1 | |
| Benzene SCHEMBL27714049 | 0.73 | MAOA (0.46) | MAOB | |
| Hydrochloric Acid SCHEMBL5625931 | 0.73 | MAOA (0.46) | MAOB | |
| SCHEMBL2919635 | 0.73 | MAOA (0.46) | MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8173644-B2 | 3-substituted-[1,2,3]-benzotriazinone compound for enhancing glutamatergic synaptic responses | LES LABORATOIRES SERVIER (FR) | 2012-05-08 | — | — | US | disclosed |
| EP-2144506-B1 | 3-SUBSTITUTED-[1,2,3]-BENZOTRIAZINONE COMPOUND FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES | CORTEX PHARMA INC (US) | 2011-10-05 | — | — | EP | disclosed |
| US-20100137295-A1 | 3-SUBSTITUTED-[1,2,3]-BENZOTRIAZINONE COMPOUND FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES | LES LABORATOIRES SERVIER (FR) | 2010-06-03 | — | — | US | disclosed |
| EP-2144506-A1 | 3-SUBSTITUTED-Ý1,2,3¨-BENZOTRIAZINONE COMPOUND FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES | CORTEX PHARMACEUTICALS, INC. (US) | 2010-01-20 | — | — | EP | disclosed |
| WO-2008085506-A1 | 3-SUBSTITUTED-[1,2,3]-BENZOTRIAZINONE COMPOUND FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES | CORTEX PHARMACEUTICALS, INC. (US) | 2008-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137295-A1 | 3-SUBSTITUTED-[1,2,3]-BENZOTRIAZINONE COMPOUND FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES | GRIN1, GRIN3B, GRIN3A | METAP1 3483/4885MMP12 3422/4885BRD4 631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.